A retrospective study published online ahead of print in the medical journal Urology by a physician team from Roswell Park Cancer Institute found that patients with metastatic kidney cancer—even those with chronic renal insufficiency—can tolerate and benefit from a treatment called high-dose interleukin-2 immunotherapy.

READ FULL ARTICLE Curated publisher From Medical News Today